DZ2320A1 - Antagonistes de récepteurs de vitronectine. - Google Patents

Antagonistes de récepteurs de vitronectine.

Info

Publication number
DZ2320A1
DZ2320A1 DZ970170A DZ970170A DZ2320A1 DZ 2320 A1 DZ2320 A1 DZ 2320A1 DZ 970170 A DZ970170 A DZ 970170A DZ 970170 A DZ970170 A DZ 970170A DZ 2320 A1 DZ2320 A1 DZ 2320A1
Authority
DZ
Algeria
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
DZ970170A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DZ2320A1 publication Critical patent/DZ2320A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials
DZ970170A 1996-10-02 1997-09-29 Antagonistes de récepteurs de vitronectine. DZ2320A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11

Publications (1)

Publication Number Publication Date
DZ2320A1 true DZ2320A1 (fr) 2002-12-28

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970170A DZ2320A1 (fr) 1996-10-02 1997-09-29 Antagonistes de récepteurs de vitronectine.

Country Status (37)

Country Link
EP (1) EP0957917B1 (fr)
JP (2) JP4491072B2 (fr)
KR (1) KR100589578B1 (fr)
CN (1) CN1114403C (fr)
AP (1) AP1463A (fr)
AR (1) AR008878A1 (fr)
AT (1) ATE312089T1 (fr)
AU (1) AU733417B2 (fr)
BG (1) BG64581B1 (fr)
BR (1) BR9712248B1 (fr)
CA (1) CA2267224C (fr)
CO (1) CO4900046A1 (fr)
CY (1) CY2576B1 (fr)
CZ (1) CZ299076B6 (fr)
DE (1) DE69734833T2 (fr)
DK (1) DK0957917T3 (fr)
DZ (1) DZ2320A1 (fr)
EA (1) EA002419B1 (fr)
ES (1) ES2252775T3 (fr)
HK (1) HK1023730A1 (fr)
HU (1) HU229221B1 (fr)
ID (1) ID19623A (fr)
IL (1) IL129243A (fr)
MA (1) MA24361A1 (fr)
MY (1) MY137606A (fr)
NO (1) NO320194B1 (fr)
NZ (1) NZ334953A (fr)
PE (1) PE10499A1 (fr)
PL (1) PL190859B1 (fr)
RO (1) RO119881B1 (fr)
SA (1) SA98180936B1 (fr)
SK (1) SK285029B6 (fr)
TR (1) TR199900737T2 (fr)
TW (1) TW487702B (fr)
UA (1) UA60311C2 (fr)
UY (2) UY24735A1 (fr)
WO (1) WO1998014192A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125866B1 (en) * 1999-04-30 2006-10-24 Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
BR9813208A (pt) * 1997-09-24 2000-08-22 Smithkline Beecham Corp Antagonista receptor de vitronectina
TR200000786T2 (tr) * 1997-09-24 2000-08-21 Smithkline Beecham Corporation Vitronektin reseptör antagonisti
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
IL143901A0 (en) * 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
WO2000046215A1 (fr) * 1999-02-03 2000-08-10 Merck & Co., Inc. Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100854424B1 (ko) 2001-01-29 2008-08-27 3-디멘져널 파마슈티칼즈 인코오포레이티드 치환된 인돌 및 인테그린 길항제로서의 이들의 용도
JP4394882B2 (ja) * 2001-04-10 2010-01-06 スミスクライン・ビーチャム・コーポレイション 接着形成阻害方法
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
US7109191B2 (en) 2001-05-03 2006-09-19 Merck & Co., Inc. Benzazepinone alpha vintegrin receptor antagonists
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
JP2006522139A (ja) * 2003-04-04 2006-09-28 スミスクライン・ビーチャム・コーポレイション ベンズアゼピンの製造方法およびその中間体
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
DK1734996T3 (da) * 2004-04-02 2013-06-10 Univ California Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200635902A (en) * 2004-12-21 2006-10-16 Smithkline Beecham Corp Methods and formulations
US20080293691A1 (en) * 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
JP5637855B2 (ja) 2007-11-08 2014-12-10 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
ES2428896T3 (es) * 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
EP2257538B1 (fr) * 2008-03-06 2016-04-27 GlaxoSmithKline LLC Procédé pour la préparation de dérivés de benzadiazépine
WO2010093706A2 (fr) 2009-02-10 2010-08-19 The Scripps Research Institute Vaccination programmée chimiquement
CN102427816A (zh) * 2009-03-30 2012-04-25 宇部兴产株式会社 用于治疗或预防眼病的药物组合物
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
KR101752515B1 (ko) 2009-07-24 2017-06-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물
JP5856063B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する1,4−ベンゾジアゼピン−2,5−ジオンおよび関連化合物
EP2325194A1 (fr) * 2009-11-24 2011-05-25 Glycotope GmbH Processus de purification de glycoprotéines
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
EP4144725A4 (fr) * 2020-04-26 2023-10-25 Jiangsu NHWA Pharmaceutical Co., Ltd Dérivé de 1,5-dihydro-2,4-benzodiazépine-3-one et son utilisation
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236882T1 (de) * 1992-12-21 2003-04-15 Smithkline Beecham Corp Bicyklische fibrinogen antagoniste
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
PL318199A1 (en) * 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
WO1996006087A1 (fr) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Composes bicycliques
WO1996026190A1 (fr) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Antagonistes des recepteurs a l'integrine
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
BR9712248A (pt) 1999-08-24
UA60311C2 (uk) 2003-10-15
CA2267224A1 (fr) 1998-04-09
UY24735A1 (es) 1998-03-30
NZ334953A (en) 2000-01-28
AP1463A (en) 2005-09-10
CN1238689A (zh) 1999-12-15
BG103299A (en) 2000-01-31
JP2001501936A (ja) 2001-02-13
CZ113299A3 (cs) 2000-03-15
ID19623A (id) 1998-07-23
EP0957917A4 (fr) 2002-05-15
PE10499A1 (es) 1999-03-27
AU733417B2 (en) 2001-05-17
PL332674A1 (en) 1999-09-27
DE69734833D1 (de) 2006-01-12
EP0957917B1 (fr) 2005-12-07
CA2267224C (fr) 2007-03-13
IL129243A (en) 2004-07-25
EP0957917A1 (fr) 1999-11-24
NO320194B1 (no) 2005-11-14
MY137606A (en) 2009-02-27
AU4746297A (en) 1998-04-24
JP4491072B2 (ja) 2010-06-30
BG64581B1 (bg) 2005-08-31
SK42599A3 (en) 1999-12-10
KR20000048816A (ko) 2000-07-25
DE69734833T2 (de) 2006-07-13
RO119881B1 (ro) 2005-05-30
CO4900046A1 (es) 2000-03-27
AP9901493A0 (en) 1999-03-31
HK1023730A1 (en) 2000-09-22
CN1114403C (zh) 2003-07-16
PL190859B1 (pl) 2006-02-28
WO1998014192A1 (fr) 1998-04-09
MA24361A1 (fr) 1998-07-01
KR100589578B1 (ko) 2006-06-15
BR9712248B1 (pt) 2010-06-29
AR008878A1 (es) 2000-02-23
ES2252775T3 (es) 2006-05-16
EA199900356A1 (ru) 2000-02-28
IL129243A0 (en) 2000-02-17
JP2010006838A (ja) 2010-01-14
CZ299076B6 (cs) 2008-04-16
UY24935A1 (es) 2001-07-31
DK0957917T3 (da) 2006-04-18
SA98180936B1 (ar) 2006-05-30
NO991590D0 (no) 1999-03-31
TW487702B (en) 2002-05-21
TR199900737T2 (xx) 1999-07-21
HUP9903769A2 (hu) 2000-03-28
ATE312089T1 (de) 2005-12-15
EA002419B1 (ru) 2002-04-25
HU229221B1 (en) 2013-09-30
SK285029B6 (sk) 2006-04-06
HUP9903769A3 (en) 2000-07-28
CY2576B1 (en) 2008-07-02
NO991590L (no) 1999-05-31

Similar Documents

Publication Publication Date Title
DZ2320A1 (fr) Antagonistes de récepteurs de vitronectine.
BR9508178A (pt) Antagonistas de receptor de vitronectina
BR9612327A (pt) Antagonistas receptores de vitronectina
BR9612378A (pt) Antagonistas receptores de vitronectina
TR199801594A3 (tr) CCR-3 reseptör antagonistleri.
NO983001D0 (no) Vitronectin-reseptor-antagonister
BR9709952A (pt) Antagonistas de receptor de il-8
NO986109D0 (no) IL-8 reseptor-antagonister
DE69812096T2 (de) Neuropeptid y rezeptorantagonisten
NO972016D0 (no) Indolyl-Y-reseptorantagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
BR9711140A (pt) Antagonistas receptores de il-8
TR199600359A2 (tr) Adezyon reseptörü antagonistleri.
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20004503D0 (no) Vitronectin-reseptor-antagonister
NO20001407D0 (no) Vitronectin-reseptor-antagonister
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001515D0 (no) Vitronektin reseptor-antagonist
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
BR9507220A (pt) Antagonistas de receptores de endotelina
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
TR199501389A2 (tr) Adesyon reseptörü antagonistleri (karsitlari).
NO20010620D0 (no) Vitronektinreseptor-antagonister
TR199601082A3 (tr) Entegrin reseptör antagonistleri.
ZA978798B (en) Vitronectin receptor antagonists.